{"member_organisations": "", "identification_number": "29570313329-11", "fields_of_interest": "Trade, Business and Industry, Environment, Research and innovation, Public Health", "head_office_address": "Novo All\u00e9, 1", "full_time_equivalent_fte": "1", "person_with_legal_responsibility": "Lars Fruergaard J\u00f8rgensen", "inter_groups": "", "financial_year_start_date": "01/01/2017", "grants": "", "head_office_country": "Denmark", "eu_initiatives": "EU Pharmaceutical related legislation (in the fields of public health, research and technology, environment, \nenterprise and trade).  \nIMI", "organisation_name": "Novo Nordisk", "belgium_office_post_code": "", "number_of_persons_involved": "2", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Companies & groups", "belgium_office_phone": "", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "", "registration_date": "13/03/2010", "website_address": "http://www.novonordisk.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Bagsv\u00e6rd", "membership": "Novo Nordisk is member of: \n \nEFPIA - European Federation of Pharmaceutical Industries and Associations  \n \nEuropaBio - European Association for Bioindustries \n \nDanish Chamber of Commerce \n \nEucomed \n \nIFPMA - International Federation of Pharmaceutical Manufacturers & Associations", "head_office_post_code": "2880", "goals__remit": "Novo Nordisk is a global healthcare company with over 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. \n \nHeadquartered in Denmark, Novo Nordisk employs approximately 40000 employees in 75 countries. It markets products and services that make a significant difference to patients, the medical profession and society in 190 countries. \n \nNovo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line). This commitment is demonstrated through its values and its environmental and social responsibility policies. \n \nThe Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its company's operations and to make contributions to scientific, humanitarian and social progress. \n \nNovo A/S is an unlisted Danish public limited liability company, owned by the Novo Nordisk Foundation and established to manage the Foundation's funds and to invest actively in other companies.  \n \nAll A and B shares in Novo Nordisk A/S, previously held by the Novo Nordisk Foundation, were transferred to Novo A/S on 31 December 1999. Novo Nordisk\u2019s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).", "industry_forums": "", "head_office_phone": "(+45)44448888", "level_of_interest": "global", "relevant_communication": "", "financial_year_end_date": "01/12/2017", "estimate_of_costs_as_a_range": "200000-299999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporation", "person_in_charge_of_eu_relations": "Jeppe Torp Vestentoft", "customers": "", "belgium_office_post_box": "", "position": "Policy Lead - Head of EU Government Affairs"}